Dexamethasone Eye Drops: Uses, Eye Pressure, and Risks

Dexamethasone eye drops are one of the most widely prescribed topical corticosteroids in ophthalmology, used primarily to control inflammation after eye surgery or to treat inflammatory conditions like uveitis. They are potent, fast-acting, and effective, but they come with a well-documented set of risks that make monitoring and proper use essential. The balance between their anti-inflammatory power and their potential to raise eye pressure or cloud the lens is something every person using them should understand.

What Dexamethasone Eye Drops Are Prescribed For

The most common reason you will be handed a bottle of dexamethasone drops is cataract surgery. After the lens is removed and replaced, the eye mounts an inflammatory response, and controlling that response is critical for a good visual outcome. In a study comparing dexamethasone to the non-steroidal anti-inflammatory drug indomethacin and the antibiotic ciprofloxacin alone, patients in the dexamethasone group had lower average inflammation scores and better final visual acuity after cataract surgery.¹ A newer fixed-dose combination of dexamethasone and the antibiotic levofloxacin has also been approved specifically for post-cataract use, with trial data showing that just one week of the combination drops (followed by a second week of dexamethasone alone) was enough to resolve inflammation and prevent infection as effectively as older two-week regimens.²

Beyond cataract surgery, dexamethasone drops are used to treat anterior uveitis, an inflammation of the middle layer of the eye that can cause pain, redness, and light sensitivity. A Phase I/II trial tested a novel dexamethasone delivery device against standard prednisolone acetate drops for noninfectious anterior uveitis and found comparable efficacy, with both treatments being safe and well tolerated.³ Dexamethasone drops are also used after other types of eye surgery, including vitreoretinal procedures, and for various surface inflammatory conditions like severe allergic conjunctivitis or certain forms of keratitis where infection has been ruled out.

How Dexamethasone Gets Into the Eye

A drop placed on the surface of the eye faces an obstacle course. Blinking, tear drainage, and the cornea’s natural barrier all work against drug absorption. Most of any single drop is washed away within minutes. When researchers measured the drug concentrations inside the eye after topical dexamethasone application, the average concentration in the aqueous humor (the fluid in the front chamber of the eye) was about 30 ng/ml, but concentrations dropped sharply deeper in, reaching only around 1 ng/ml in the vitreous and less than 1 ng/ml in the bloodstream.⁴ This steep drop-off is actually good news: it means topical dexamethasone delivers a useful dose to the front of the eye while keeping systemic exposure extremely low.

The formulation of the drop matters. Modeling studies in rabbits have shown that viscosity plays a bigger role than particle size in determining how much drug the eye actually absorbs. A thicker drop stays on the eye surface longer before being drained away, increasing the window for absorption. Once the formulation is viscous enough, though, further thickening stops helping because you have hit the limit of how long anything can resist the eye’s natural clearance mechanisms.⁵ Researchers have also found that formulating dexamethasone with cyclodextrin molecules can push significantly higher drug concentrations into the aqueous humor compared to standard dexamethasone alcohol drops.⁶

The Main Risk: Rising Eye Pressure

If there is one thing to know about dexamethasone eye drops, it is that they can raise intraocular pressure (IOP). This is not a rare side effect or a theoretical concern; it is a well-characterized pharmacological response. In laboratory-perfused human eyes, about a third of eyes treated with dexamethasone developed a significant pressure increase, averaging roughly 17.5 mmHg above baseline after 12 days of exposure, while the untreated control eyes remained stable. The tissue changes were visible under microscopy: thickened drainage structures and accumulation of material that impedes fluid outflow.⁷

Not everyone’s eyes respond the same way. A long-term follow-up study categorized people into high, intermediate, and low steroid responders based on how much their IOP climbed during dexamethasone administration. Among high responders (pressure rising above 31 mmHg), about 13% went on to develop glaucomatous visual field loss over the follow-up period. Among intermediate responders (pressure between 20 and 31 mmHg), only about 3.4% developed field loss, and among low responders, none did.⁸ This means your individual pressure response to steroid drops is actually a meaningful predictor of future glaucoma risk, which is one reason your eye doctor checks your pressure at follow-up visits when you are on these drops.

Even short-term use can cause a measurable bump. In patients with glaucoma, a single pharmacologic dose of dexamethasone raised IOP by about 2 mmHg in the first four hours and about 5.5 mmHg between four and eight hours afterward.⁹ For someone with already borderline pressure, those numbers are not trivial.

Cataracts and Delayed Healing

Prolonged use of any topical corticosteroid carries a risk of posterior subcapsular cataract, a specific clouding at the back surface of the lens. This has been observed after as little as four months of topical steroid use and is thought to result from the drug binding to lens proteins and triggering oxidative damage.¹⁰ In a short four-week trial of dexamethasone-cyclodextrin eye drops for diabetic macular edema, no noticeable cataract formation was detected on standard slit-lamp examination, but the authors acknowledged that the study was too short to meaningfully evaluate this risk and that longer exposure would need more sensitive imaging.¹¹ The practical takeaway is that short courses after surgery are unlikely to cause cataracts on their own, but if you end up needing steroid drops for months, the lens needs to be monitored.

Dexamethasone also slows corneal wound healing. In rabbit models with corneal injuries, applying 0.1% dexamethasone immediately after the injury delayed healing and produced more corneal haze compared to untreated eyes.¹² A separate study on alkali-burned corneas confirmed that 0.1% dexamethasone retarded the epithelial repair process and, when used for eight weeks, triggered intense inflammatory cell infiltration in the stroma once treatment stopped.¹³ This is why ophthalmologists are cautious about starting steroid drops when a corneal epithelial defect is still open. The general rule is to wait until the surface has healed before introducing dexamethasone.

The Infection Trade-Off

Corticosteroids suppress the immune response. That is exactly why they reduce inflammation, but it is also why they can allow infections to take hold or worsen. Fungal keratitis is the most feared scenario. In animal models, eyes treated with topical dexamethasone showed more aggressive Candida growth compared to controls, with reduced immune cell activity and inhibition of the nets that immune cells form to trap pathogens.¹⁴ This is why dexamethasone drops should never be used when a fungal infection is suspected and why combination drops that pair dexamethasone with an antibiotic are preferred after surgery: the antibiotic covers bacterial risk while the steroid handles inflammation.

How Dexamethasone Compares to Other Steroid Drops

Dexamethasone is not the only topical steroid available. Prednisolone acetate 1% is its chief rival, and the comparison between the two is genuinely interesting because neither one clearly wins across the board. In a randomized trial after cataract surgery, fluorophotometric measurements showed slightly lower inflammation in the dexamethasone group than the prednisolone group, but the difference did not reach statistical significance, leading the authors to conclude they could not demonstrate a practical difference in efficacy despite dexamethasone being the more potent molecule in terms of receptor binding.¹⁵ However, a study of small-incision cataract surgery in Indian patients actually found prednisolone acetate to be more effective than dexamethasone sodium in the early post-operative period, controlling inflammation with a statistically significant advantage.¹⁶

The formulation explains part of this. Dexamethasone sodium phosphate is a water-soluble salt that penetrates the cornea less aggressively than prednisolone acetate, which is a suspension of drug particles that dissolve more slowly and penetrate better into the aqueous humor. Dexamethasone alcohol (a different formulation) has better corneal penetration than the sodium phosphate version, which is why formulation details matter beyond just which drug name is on the label.

Loteprednol etabonate is another alternative, designed specifically to have a lower pressure-raising profile. In a trial of 306 healthy volunteers treated four times daily for four weeks, about 7.5% of those on dexamethasone/tobramycin experienced IOP spikes of 10 mmHg or more, compared to only about 2% of those on loteprednol/tobramycin. The dexamethasone group showed significant mean IOP elevation at every study visit, while the loteprednol group did not.¹⁷ A smaller comparative study in post-cataract patients confirmed this pattern: after four weeks of treatment, about 9% of dexamethasone-treated patients had an IOP rise of 5 mmHg or more, versus none in the loteprednol group.¹⁸ The trade-off is that loteprednol is generally considered somewhat less potent against severe inflammation, so your surgeon may choose dexamethasone when the inflammatory load is expected to be high and switch you to loteprednol for longer-term maintenance.

When a Non-Steroidal Drop Might Work Instead

Non-steroidal anti-inflammatory drugs (NSAIDs) like diclofenac, ketorolac, and nepafenac are available as eye drops and avoid the pressure and cataract risks of steroids entirely. In a comparison between topical diclofenac and dexamethasone after retinal detachment surgery, the two drugs controlled post-operative inflammation equally well at every measured time point, with no significant difference in aqueous flare. Interestingly, diclofenac actually beat dexamethasone on pain control, producing significantly lower pain scores in the weeks after surgery.¹⁹ Broader reviews of post-cataract drops suggest that while overall inflammation outcomes between NSAIDs and steroids are often statistically similar, steroids tend to clear inflammatory cells from the anterior chamber more quickly in the first few days.²⁰ Many surgeons use both concurrently, relying on the steroid for the initial heavy inflammatory response and the NSAID for longer-term comfort and to reduce the risk of cystoid macular edema.

Combination Drops With Antibiotics

Rather than juggling separate steroid and antibiotic bottles, many post-surgical regimens use a fixed combination. Tobramycin/dexamethasone (sold under various brand names) is one of the most established. A multicenter trial found that the combination was significantly better at controlling post-cataract inflammation than tobramycin alone, confirming that the steroid component is doing real work in these combination products.²¹ A comparison of netilmicin/dexamethasone (a preservative-free combination) against tobramycin/dexamethasone after cataract surgery found both safe and effective, though the tobramycin combination showed a slightly faster anti-inflammatory effect. The study noted that the tobramycin combination requires IOP monitoring, reinforcing the pressure concern even in short-course use.²²

Dexamethasone/netilmicin combinations have also been tested after vitreoretinal surgery, including in a gel formulation that requires fewer applications per day. The gel was found to be safe and effective, with high patient tolerability.²³ The convenience factor matters. Fewer bottles and simpler schedules tend to improve how consistently people actually use their drops, which is a perennial problem in ophthalmology.

Children Are More Sensitive

If you are a parent whose child has been prescribed dexamethasone drops after surgery, be aware that children’s eyes tend to show a more dramatic pressure response than adults’. A study comparing twice-daily versus four-times-daily dexamethasone in children found that both dosing schedules produced a significant IOP rise compared to pre-treatment levels. The twice-daily group saw an average peak pressure of about 25 mmHg (up from about 14 mmHg before treatment), while the four-times-daily group reached nearly 29 mmHg. The dose-dependent nature of the response was clear: more frequent drops meant higher peak pressure.²⁴ This does not mean children cannot use dexamethasone drops, but it does mean that follow-up pressure checks are especially important and that the lowest effective dose and shortest possible course should be the goal.

Getting the Most Out of Each Drop

Technique matters more than most people realize. When you put a drop in your eye, much of it immediately drains down the nasolacrimal duct (the passage from the inner corner of your eye into your nose and throat). Closing your eyelids gently for a minute or two after instillation, or pressing lightly on the inner corner of your eye to block that drain, has been shown to improve how much drug stays in the eye and reduce the amount absorbed into your bloodstream.²⁵ For dexamethasone specifically, maximizing local absorption and minimizing systemic absorption is desirable because you want the drug in the eye, not circulating through the rest of your body.

If you are on multiple eye drops, spacing them at least five minutes apart prevents one drop from washing the previous one off the eye surface before it has been absorbed. Shaking the bottle before use is also important for suspension formulations, where the active drug particles settle to the bottom. Dexamethasone sodium phosphate is a solution and does not need shaking, but prednisolone acetate (a suspension) does, and mixing up which one you are using can lead to under-dosing.

Preservative-Free Formulations and Dry Eye

Most traditional eye drop bottles contain preservatives, with benzalkonium chloride being the most common. These preservatives can irritate the ocular surface, particularly for people who already have dry eye or who are using multiple medicated drops throughout the day. After cataract surgery, dry eye symptoms are common regardless of the drops used, and research has shown that patients with pre-existing dry eye who were treated with preservative-free post-operative drops saw improvement in their dry eye signs after surgery.²⁶ If you have a history of dry eye and are prescribed post-surgical drops, asking your surgeon about preservative-free options is reasonable. The drug itself is the same; you are just avoiding the irritant that comes along for the ride in the standard bottle.

Emerging Delivery Technologies

Standard eye drops are effective but inefficient: most of the drug is wasted, and you have to remember to use them multiple times a day. Researchers are working on formulations that keep the drug on or near the eye surface longer, reducing dosing frequency and improving how much drug actually reaches its target. Mucoadhesive hydrogels containing cyclodextrin have shown enhanced bioavailability over conventional drops by sticking to the eye’s mucus layer and releasing dexamethasone slowly.²⁷ Supramolecular hydrogels made from dexamethasone prodrug derivatives represent another approach, forming gel-like structures that provide prolonged retention on the cornea and significantly increased drug levels in the eye compared to standard aqueous solutions.²⁸ Nanoparticle systems using materials like chitosan are also being developed specifically for conditions like anterior uveitis, aiming to deliver sustained drug release right where it is needed while reducing the total amount of drug required.²⁹

None of these advanced systems have replaced the standard dropper bottle for most patients yet, but they signal where the field is headed. The goal is drops (or gels, or inserts) that you use once a day or less, that deliver a steadier drug level, and that minimize the peaks and troughs that contribute to side effects like pressure spikes. For a drug as effective and as tricky as dexamethasone, better delivery could meaningfully change the risk-benefit equation.